Rep. Greg Walden, chairman of the House Energy and Commerce Committee, on Thursday announced plans to consider legislation aimed at speeding Food and Drug Administration approvals of off-patent drugs that face scant competition.
The Oregon Republican said the bipartisan legislation would provide incentives for generic drug development.
